Developing New, Rational Therapies for Recalcitrant Small Cell Lung Cancer
Menée sur 63 lignées cellulaires de carcinome du poumon à petites cellules, cette étude évalue la réponse à 103 agents thérapeutiques ayant reçu une autorisation de mise sur le marché américain et 423 agents en cours d'évaluation
The Recalcitrant Cancer Research Congressional Act of 2012 (H.R.733) directs the National Cancer Institute (NCI) to utilize resources for research and treatment of recalcitrant cancers having five-year relative survival rates of less than 20% that have not seen substantial progress in diagnosis or treatment. The initial focus will be on pancreatic carcinoma and small cell cancer of the lung (SCLC). SCLC is strongly associated with tobacco exposure and is characterized by rapid growth, early metastasis, and a five-year survival rate of less than 7%. The basic therapeutic approach for SCLC has remained unchanged for three decades, and no effective targeted therapies exist to date (1,2). SCLC is a poster child for recalcitrant cancers as documented in subsequent NCI responses and workshop proceedings (3,4).
Journal of the National Cancer Institute , éditorial en libre accès, 2016